Cargando…

Oral cladribine treatment and idiosyncratic drug-induced liver injury in multiple sclerosis

BACKGROUND: Oral cladribine (OC) is approved for the treatment of highly active relapsing multiple sclerosis. Postmarketing safety assessments have reported rare, but occasionally severe cases of liver injury in temporal association with OC, with pathophysiologic mechanisms still unknown. In the onl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rakers, Florian, Fritsch, Almut, Herrmann, Andreas, Tannapfel, Andrea, Schwab, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496679/ https://www.ncbi.nlm.nih.gov/pubmed/37705760 http://dx.doi.org/10.1136/bmjno-2023-000481

Ejemplares similares

COVID-19 in Cladribine-treated patient with multiple sclerosis
por: Haham, Nitsan, et al.
Publicado: (2021)

Idiosyncratic drug-induced liver injury caused by givosiran in a patient with acute intermittent porphyria
por: Ma, Christopher D., et al.
Publicado: (2022)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Idiosyncratic Liver Injury Due to Levocetirizine
por: Annunziata, Giuseppe, et al.
Publicado: (2019)

Immune mechanisms of idiosyncratic drug-induced liver injury
por: Mak, Alastair, et al.
Publicado: (2017)

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
por: Murphy, Julie A, et al.
Publicado: (2010)

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
por: De Stefano, Nicola, et al.
Publicado: (2017)

Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury
por: Kim, Seung-Hyun, et al.
Publicado: (2016)

Idiosyncratic drug‐induced liver injury: A short review
por: Yamashita, Yo‐ichi, et al.
Publicado: (2017)

Treatment of Idiosyncratic Drug-Induced Liver Injury Using Steroids
por: Sundaram, Suneha, et al.
Publicado: (2020)

Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges
por: Jee, Alison, et al.
Publicado: (2021)

Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment
por: Schönfelder, Kristina, et al.
Publicado: (2021)

Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine
por: Schreiner, Teri L., et al.
Publicado: (2012)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
por: Moiola, Lucia, et al.
Publicado: (2022)

Molecular signature associated with cladribine treatment in patients with multiple sclerosis
por: Fissolo, Nicolas, et al.
Publicado: (2023)

Stem Cell Strategies to Evaluate Idiosyncratic Drug-induced Liver Injury
por: Krueger, Winfried, et al.
Publicado: (2014)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
por: Pakpoor, Julia, et al.
Publicado: (2015)

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
por: Ceronie, Bryan, et al.
Publicado: (2018)

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis
por: Afolabi, Dayo, et al.
Publicado: (2017)

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
por: Rammohan, Kottil, et al.
Publicado: (2020)

COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
por: Jack, Dominic, et al.
Publicado: (2021)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Cladribine repurposed in multiple sclerosis: making a fortune out of a generic drug
por: Buiter, Hans J C, et al.
Publicado: (2019)

Protocol for a Cross-Sectional Study: Effects of a Multiple Sclerosis Relapse Therapy With Methylprednisolone on Offspring Neurocognitive Development and Behavior (MS-Children)
por: Kozik, Valeska, et al.
Publicado: (2022)

Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays
por: Roth, Alexander D., et al.
Publicado: (2017)

Metamizole: An underrated agent causing severe idiosyncratic drug‐induced liver injury
por: Sebode, Marcial, et al.
Publicado: (2020)

Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues
por: Teschke, Rolf, et al.
Publicado: (2021)

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
por: Mateo-Casas, M., et al.
Publicado: (2020)

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
por: Michels, Renée Else, et al.
Publicado: (2019)

Outcomes of COVID-19 in people with multiple sclerosis treated with cladribine tablets: an update
por: Jack, Dominic, et al.
Publicado: (2021)

Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis
por: Nabizadeh, Fardin, et al.
Publicado: (2023)

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
por: Rolfes, Leoni, et al.
Publicado: (2023)

Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
por: Clavelou, Pierre, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_joimvfdau6at0v1o42ks2602fn